MASSA, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 305
EU - Europa 196
AS - Asia 80
AF - Africa 45
Totale 626
Nazione #
US - Stati Uniti d'America 305
IT - Italia 75
SE - Svezia 56
SG - Singapore 51
CI - Costa d'Avorio 32
AT - Austria 25
IN - India 16
BG - Bulgaria 13
GB - Regno Unito 12
SN - Senegal 7
CN - Cina 6
NG - Nigeria 6
DE - Germania 5
PL - Polonia 5
HK - Hong Kong 3
VN - Vietnam 3
RO - Romania 2
CZ - Repubblica Ceca 1
FR - Francia 1
LK - Sri Lanka 1
UA - Ucraina 1
Totale 626
Città #
Chandler 55
Fairfield 37
Abidjan 32
Vienna 25
New York 18
Milan 17
Singapore 17
Boardman 16
Seattle 15
Florence 14
Hyderabad 13
Sofia 13
Woodbridge 13
Wilmington 12
London 9
Lawrence 8
Princeton 8
Ann Arbor 7
Cambridge 7
Dakar 7
San Diego 7
Lagos 6
Pisa 6
Ashburn 5
Ogden 5
Houston 4
Warsaw 4
Beijing 3
Cascina 3
Center 3
Frankfurt am Main 3
Hong Kong 3
Los Angeles 3
Medford 3
Santa Croce sull'Arno 3
Castiglione Chiavarese 2
Council Bluffs 2
Kent 2
Lucca 2
Norwalk 2
Philadelphia 2
Rome 2
Santa Clara 2
Serra 2
Vicopisano 2
Bremen 1
Changsha 1
Formigine 1
Fort Worth 1
Fulham 1
Garbagnate Milanese 1
Hangzhou 1
Marseille 1
Minneapolis 1
New Delhi 1
North Charleston 1
Olomouc 1
Pietrasanta 1
Redwood City 1
Stuttgart 1
Vicenza 1
Totale 440
Nome #
Early Tumor Shrinkage and Depth of Response Evaluation in Metastatic Pancreatic Cancer Treated with First Line Chemotherapy: An Observational Retrospective Cohort Study 112
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel 79
Immune checkpoint inhibitors in esophageal cancers: Are we finally finding the right path in the mist? 70
Gemcitabine plus nab-paclitaxel induces PD-L1 mRNA expression in plasma-derived microvesicles in pancreatic cancer 69
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age? 61
Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer 45
Impact of COVID-19 outbreak on cancer immunotherapy in Italy: A survey of young oncologists 43
The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib 34
Primary Resistance to Immunotherapy-Based Regimens in First Line Hepatocellular Carcinoma: Perspectives on Jumping the Hurdle 31
Equivalent efficacy but different safety profiles of gemcitabine plus nab-paclitaxel and folfirinox in metastatic pancreatic cancer 29
Predictive significance of circulating histones in hepatocellular carcinoma patients treated with sorafenib 24
Dynamic profiling of the immune tumor microenvironment in locally advanced gastric cancer treated with perioperative chemotherapy 20
Mismatch Repair Deficiency in Biliary Tract Cancer: Prognostic Implications and Correlation with Histology 12
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 8
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 7
Network meta-analysis of adjuvant chemotherapy in biliary tract cancers: Setting the scene for new randomized evidence 7
Totale 651
Categoria #
all - tutte 3.033
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.033


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202038 0 0 0 4 4 5 4 5 4 3 6 3
2020/202153 1 2 2 3 0 19 2 3 8 1 3 9
2021/202281 0 0 0 3 12 27 3 1 3 9 7 16
2022/2023250 18 33 18 11 28 33 2 25 62 0 16 4
2023/2024161 11 15 23 8 17 14 24 2 1 8 13 25
2024/202556 1 33 20 2 0 0 0 0 0 0 0 0
Totale 651